New phase 3 and 4 trials: 53 in the week of Oct. 19, against a median of 80

ClinicalTrials.gov recorded 53 new phase 3 and phase 4 trial registrations in the week beginning Monday, Oct. 19, against a median of 80 a week over the 17 earlier weeks, according to the registry's own records. The week ranks at the 6th percentile of 16 earlier complete weeks; those weeks had a median of 78.5 and a typical spread of about 7 records a week.

A phase 3 trial is the large study, usually with hundreds or thousands of participants, that tests a treatment against a standard therapy or a placebo before regulators weigh approval; phase 4 trials are run after a treatment is in use. A registration is a plan filed before results exist, so the weekly figure counts studies being posted, not studies that succeeded. Individual registry entries state the sponsor, the design and the planned enrollment; this weekly count does not.

Under 42 CFR Part 11, the federal rule for clinical trial registration and results submission, an applicable clinical trial is registered no later than 21 calendar days after the first participant is enrolled. Registration is the field's form of preregistration: the entry fixes the sponsor, the phase and the outcomes in advance, which is what lets later results be checked against the original plan.

One of the week's postings is a Cleveland Clinic trial of a nerve block intended to prevent an irregular heartbeat after cardiac surgery, filed as NCT07893275 on ClinicalTrials.gov. The registry's phase 3 and 4 totals are the source for every figure here.

Room for disagreement

One week is a thin basis for reading a trend: the count sits at the 6th percentile of 16 earlier complete weeks, and a reader could treat 53 as ordinary week-to-week variation around the median rather than a change in the pace of registration.